Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Core Insights - Exagen Inc. has appointed Jeffrey G. Black as the new Chief Financial Officer (CFO), effective September 1, 2024, replacing Kamal Adawi who is stepping down [1][2] - John Aballi, President and CEO of Exagen, expressed gratitude towards Kamal Adawi for his leadership over the past decade and emphasized the importance of a smooth transition for the company [2] - Jeffrey G. Black brings over 30 years of financial and accounting experience, having held CFO positions in multiple publicly traded companies, including Standard BioTools and Apollo Endosurgery [2][3] - Black's previous achievements include leading a successful merger at Standard BioTools and facilitating a $650 million sale at Apollo Endosurgery [2] - The leadership team at Exagen is optimistic about Black's appointment, viewing it as a pivotal moment for the company's growth and impact on patient care [3] Company Overview - Exagen Inc. is a leading provider of autoimmune testing solutions, aiming to improve decision-making in autoimmune disease and enhance clinical outcomes for patients [4]